Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

The $2.2 billion deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and ...

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...